Common Contracts
11 similar Sales Agreement contracts by AGNC Investment Corp., RAPT Therapeutics, Inc., Trevi Therapeutics, Inc., others
SCHRÖDINGER, INC. Shares of Common Stock ($0.01 par value per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • February 28th, 2024 • Schrodinger, Inc. • Pharmaceutical preparations • New York
Reference is made to that certain Sales Agreement, entered into as of May 24, 2023 (the “Original Sales Agreement”) by and between Schrödinger, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC (the “Agent”). The Company and the Agent now intend to enter into this Amended and Restated Sales Agreement (this “Agreement”) to amend and restate the terms of the Original Sales Agreement in its entirety. Therefore, the Company confirms its agreement with the Agent as follows:
RAPT Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 11th, 2023 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
On the date hereof, RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), has filed or will file with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 that contains a base prospectus as well as a sales agreement prospectus covering the offering, issuance and sale by the Company of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150,000,000. The parties agree to be legally bound by the terms of this Agreement effective immediately upon such registration statement being declared effective by the Commission.
NEXTCURE, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • August 4th, 2023 • NextCure, Inc. • Pharmaceutical preparations • New York
NextCure, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Trevi Therapeutics, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • June 29th, 2023 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
RAPT Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • November 4th, 2020 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated (each, an “Agent,” and collectively, the “Agents”), as follows:
Mereo BioPharma Group plc American Depositary Shares Each Representing Five Ordinary Share (Nominal Value £0.003 per ordinary share) SALES AGREEMENTSales Agreement • October 6th, 2020 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales with registered number 09481161 (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
Trevi Therapeutics, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • June 26th, 2020 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
0.01 PAR VALUE PER SHARE) SALES AGREEMENTSales Agreement • June 14th, 2018 • AGNC Investment Corp. • Real estate investment trusts • New York
The Company has also entered into separate sales agreements (the “Alternative Sales Agreements”), dated as of even date herewith, with each of [Ÿ], [Ÿ], [Ÿ], and [Ÿ].
0.01 PAR VALUE PER SHARE) SALES AGREEMENTSales Agreement • August 2nd, 2017 • MTGE Investment Corp. • Real estate investment trusts • New York
MTGE Investment Corp., a Maryland corporation (the “Company”), and MTGE Management, LLC, a Delaware limited liability company and manager of the Company (the “Manager”), confirm their agreement (this “Agreement”) with Wells Fargo Securities, LLC (the “Agent”), as follows:
0.01 PAR VALUE PER SHARE) SALES AGREEMENTSales Agreement • February 1st, 2017 • AGNC Investment Corp. • Real estate investment trusts • New York
AGNC Investment Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Wells Fargo Securities, LLC (the “Agent”), as follows:
0.01 PAR VALUE PER SHARE) SALES AGREEMENTSales Agreement • February 1st, 2017 • AGNC Investment Corp. • Real estate investment trusts • New York
AGNC Investment Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
